1 Senior Editor of “What’s Happening” Section of This “What’s happening” section focuses on two original DDR rojects related to platelets, coming from two of my grand coleagues with whom we have often published collaborative works. eedless to say that, as the senior editor of this section, this imonthly section is open to everyone and I welcome all colleagues nd readers who are teacher at heart and willing to share their xpert views with all readers of Transfusion and Apheresis Science, n a fast-tracked manner. In the first paper Laura Gutiérrez with her multidiscilinary research team leads a research project on the “Basal nd transfusion-related qualitative platelet alterations in the nco-hematologic patients”, a topic of current interest to all hemaological laboratories and clinicians involved in treating serious emato-oncological abnormalities. Clinically, in onco-hematology patients with chemotherapynduced thrombocytopenia, the platelet transfusion corrected ount increment (CCI) does not always correlate with expected vales and platelet transfusion does not prevent bleeding, for some nknown reason, leading to a situation of “low efficacy of platelet ransfusion”. Laura’s group therefore aimed at immunophenotypng the expression of typical platelet surface and activation markers nd thrombopoietin levels from onco-hematologic patients before nd after transfusion, including a follow-up of certain patients that nderwent autologous bone marrow transplantation. They provide vidence-based information that platelet activation does occur in nco-hematologic patients and also give useful additional interretation of platelet acquired qualitative changes in these patients: rst, patient’s own or long-circulating transfused platelets experince basal activation and loss of expression of susceptible receptors otentially by shedding and secondly, newly transfused platelets ndergo another sort of platelet activation soon after transfusion, ossibly involving platelet receptor recycling and potential loss of he activated platelets through clearance or DIC. The concept that there is a difference between basal and ransfusion-related platelet alterations in the oncohematologic atient is rather a novel notion and worth exploring in other patient ohorts, in order to contribute to the personalization or improveent of platelet transfusion support regimes, specially in refractory onditions. Validation on large cohorts of negative and positive atients remains the key approach for defining the performance nd clinical usefulness of those assays. Watch this space for more nteresting data from the same authors.